The dealmaking spree reshaping big pharma pipelines

Thursday, April 30, 2026 | 12:00 PM - 1:00 PM ET

Something shifted in the second half of 2025. After years of despondency, big pharma started writing serious checks — snapping up biotech assets at a pace that reminded the industry what an open dealmaking environment actually looks like.

That momentum hasn't slowed. The names doing the buying are familiar. And the message to the rest of biotech is clear — if you're working in the right areas, pharma is paying attention.

What does it mean for the R&D 15 going into the rest of 2026? John Carroll has been tracking these pipelines for over a decade. Tune in to hear him break it down in real-time.

The agenda is live — join us.

SPONSORED BY

Sponsorship opportunities are available.
Contact Meg at mestacio@endpointsnews.com to learn how you can support Endpoints' R&D 15 2026.

Questions about registration? Contact our support team.